Mitsugi Furukawa

Overexpression of PIAS3 Suppresses Cell Growth, Restores the Drug Sensitivity of Human Lung Cancer Cells in Association with PI3-K/Akt Inactivation

Yoshitaka Ogata, Tadashi Osaki, Tetsuji Naka et al. · Neoplasia · 2006 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Polymorphisms of CYP2D6 Gene and Gefitinib-Induced Hepatotoxicity

Takayuki Takimoto, Takashi Kijima, Yasushi Otani et al. · Clinical Lung Cancer · 2013 · 56 citations

Medicine, Pharmacokinetics, Pharmacology +14

Safe and Successful Treatment With Erlotinib After Gefitinib-Induced Hepatotoxicity: Difference in Metabolism As a Possible Mechanism

Takashi Kijima, Tomohito Shimizu, Shinpei Nonen et al. · Journal of Clinical Oncology · 2011 · 52 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

A Phase I/II Study Comparing Regimen Schedules of Gemcitabine and Docetaxel in Japanese Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Kaoru Matsui, Tomonori Hirashima, Takashi Nitta et al. · Japanese Journal of Clinical Oncology · 2005 · 21 citations

Medicine, Oncology, Pharmacology +13

Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis

Mitsugi Furukawa, Izumi Nagatomo, Toru Kumagai et al. · DNA and Cell Biology · 2007 · 17 citations

Life Sciences, Molecular Biology, Oncology +16